ArticleNature2022
Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Pooled it
- Large serine recombinase-mediated gene insertion for high-throughput screens: advantages, design principles, and applications.Nucleic acids research · 2026Review
- Discovery of Cyclic Peptides Targeting the BRAF Dimer Interface as Dual Inhibitors.ACS pharmacology & translational science · 2026Article
- SHOC2 Is a Novel Cause of Central Conducting Lymphatic Anomaly.American journal of medical genetics. Part A · 2026Article
- Molecular dynamics simulations of intrinsically disordered protein regions enable biophysical interpretation of variant-effect predictors.HGG advances · 2026Article
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Target-driven machine learning-enabled virtual screening (TAME-VS) enables prioritization of AKR1C3 inhibitors.Communications chemistry · 2026Article
- Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRASScientific reports · 2026Article
- Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass.The Biochemical journal · 2026Review
- Analysis of the Modulation of RAF Signaling by 14-3-3 Proteins.Bulletin of mathematical biology · 2026Article
- Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells.Cell death discovery · 2026Article
- Positive cooperativity between RAS-binding and cysteine-rich domains regulates RAF membrane binding kinetics via lateral rebinding.Nature communications · 2026Article
- Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.Nature communications · 2026Article
- Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.bioRxiv : the preprint server for biology · 2026Article
- Deep Mutational Scanning of FDX1 Identifies Key Structural Determinants of Lipoylation and Cuproptosis.Nature communications · 2025Article
- An in vitro BRAF activation assay elucidates molecular mechanisms driving disassembly of the autoinhibited BRAF state.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma.JCI insight · 2025Article
- Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation.Nature communications · 2025Article
- CEMIP Maintains Vascular Contractility by Controlling PP1c-MLC20 Cascade in SMCs.Circulation research · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
25 authors at 5 institutions in 1 country.
Jason J Kwon *Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Behnoush Hajian *Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Yuemin Bian *Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5845-772X
Lucy C Young *Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Alvaro J AmorCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
James R FullerHelix Biostructures, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-9029-0923
Cara V FraleyCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Abbey M SykesHarvard Medical School, Boston, Massachusetts, USA.
Jonathan SoCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Joshua PanCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Laura BakerCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Sun Joo LeeCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Douglas B WheelerCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
David L MayhewCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Nicole S PerskyGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Xiaoping YangGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6811-4915
David E RootGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5122-861X
Anthony M BarsottiDeerfield Discovery and Development, Deerfield Management, New York, NY, USA.
Andrew W StamfordDeerfield Discovery and Development, Deerfield Management, New York, NY, USA.
Charles K PerryCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Alex BurginCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Frank McCormickHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6619-7120
Christopher T LemkeCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. clemke@broadinstitute.org.
William C HahnCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. william_hahn@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-2840-9791
Andrew J AguirreCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. andrew_aguirre@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-0701-6203
Broad Institute · USDeerfield (United States) · USHelix Biomedix (United States) · USLeidos (United States) · USUniversity of California, San Francisco · US
Funding
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MPROJECT 4: Interrogating PP2A Signaling in Human CancersP01CA203655 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2017 to 2021
$8.0MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MNew Ways of Targeting K-RasR35CA197709 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCORMICK, FRANK PATRICK · 2016 to 2022
$6.7MSystematic interrogation of the pancreatic cancer microenvironment in patient-derived specimensU01CA224146 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2017 to 2021
$3.0MDevelopment and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer modelsU01CA250549 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2020 to 2022
$2.9MFunctional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancerK08CA218420 · NCI · DANA-FARBER CANCER INST · PI AGUIRRE, ANDREW JAMES · 2017 to 2021
$886kElucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancerF32CA243290 · NCI · DANA-FARBER CANCER INST · PI KWON, JASON · 2019 to 2021
$192kNCI NIH HHS F32 CA243290NCI NIH HHS K08 CA218420NCI NIH HHS P01 CA203655NCI NIH HHS P50 CA127003NCI NIH HHS R35 CA197709NCI NIH HHS U01 CA176058NCI NIH HHS U01 CA224146NCI NIH HHS U01 CA250549
Abstract
Receptor tyrosine kinase (RTK)-RAS signalling through the downstream mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation and survival. The SHOC2-MRAS-PP1C holophosphatase complex functions as a key regulator of RTK-RAS signalling by removing an inhibitory phosphorylation event on the RAF family of proteins to potentiate MAPK signalling
Indexed as
Cryoelectron MicroscopyIntracellular Signaling Peptides and ProteinsMultiprotein ComplexesProtein Phosphatase 1ras ProteinsAmino Acid MotifsBinding SitesGuanosine TriphosphateHumansMAP Kinase Signaling SystemMutation, MissensePhosphorylationProtein BindingProtein Stabilityraf KinasesGuanosine TriphosphateIntracellular Signaling Peptides and ProteinsMRAS protein, humanMultiprotein ComplexesProtein Phosphatase 1raf Kinasesras ProteinsSHOC2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.